FORCE and researchers at the University of South Florida formed the ABOUT Patient-Powered Network to help advance hereditary cancer research through collaborations. See below for more information about each project, FORCE's role, and the status of the research.
Nadine Tung, MD
Type of Research:
Olaparib Expanded Trial
Olaparib Expanded is a study looking at whether the drug olaparib is effective treatment for people with certain types of metastatic breast cancer. Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors have been approved for treating advanced breast cancer in people with an inherited BRCA1 or BRCA2 mutation. Olaparib Expanded is looking at the effects of PARP inhibitors for treating breast cancer in people without an inherited BRCA1 or BRCA2 mutation.
The study is looking at olaparib to treat metastatic breast cancer in two specific groups of patients who have tested negative for a BRCA mutation:
- People with metastatic breast cancer whose tumor has a somatic mutation in BRCA1 or BRCA2. This means that although the patient does not have an inherited BRCA mutation, their tumor cells have developed mutations in either of these genes.
- Patients with an inherited mutation or tumor mutation in one of the other genes (i.e. ATM, CHEK2, NBN, PALB2, RAD50, RAD51C/D) that functions with BRCA1 and BRCA2 to repair damaged DNA.
This study is currently enrolling patients. You can read more about enrolling in the Olaparib Expanded study.
FORCE and ABOUT Network roles
FORCE is assisting the enrollment effort by promoting the study.
Although this study is still enrolling patients, early results have been reported by the researcher. You can read these early results in this XRAY article, Study: Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2.
This research is relevant for:
People diagnosed with breast cancer
People in treatment
People with metastatic or advanced disease